COMP <GO>
HCA vs JNJ // 10Y YIELD & FRED MACRO BETA
HCA Healthcare Inc. (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: HCA 6
— JNJ 6
▲ 10Y YIELD & FRED MACRO BETA LEADER: JNJ
LAST: $478.08 (+3.21%) • MKT CAP: $103.51B
macro-sensitivity
1.04
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
macro-sensitivity
1.08
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HCA VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HCA | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 67.90% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 18.90% | 25.50% | -6.60 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 11.5x | 18.5x | -7.00 | HCA | /valuation <GO> |
| Free Cash Flow Yield | 7.43% | 2.97% | +4.46 | HCA | /fcf-yield <GO> |
| Operating Margin | 10.90% | 34.70% | -23.80 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 9.00% | 28.50% | -19.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 7.10% | 6.00% | +1.10 | HCA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.66% | 0.00% | +0.66 | HCA | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.68 | 5.59 | -1.91 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 62.6 | 62.1 | +0.50 | HCA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 1.04 | 1.08 | -0.04 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 14.2x | 23.0x | -8.80 | HCA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $103.51B | $662.49B | -$558.99B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HCA REV | JNJ REV | HCA GROSS % | JNJ GROSS % | HCA FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $75.60B | $94.19B | — | 67.9% | $7.69B | $19.70B |
| FY 2024 | $70.60B | $88.82B | — | 69.1% | $5.64B | $19.84B |
| FY 2023 | $64.97B | $85.16B | — | — | $6.51B | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HCA // BETA 1.04
JNJ // BETA 1.08